Alnylam Pharmaceuticals, Inc. (FRA:DUL)
Germany · Delayed Price · Currency is EUR | Market Cap | 27.95B -44.1% |
| Revenue (ttm) | 4.21B +95.1% |
| Net Income | 678.10M |
| EPS | 4.92 |
| Shares Out | n/a |
| PE Ratio | 41.22 |
| Forward PE | 20.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 209.70 |
| Previous Close | 207.80 |
| Day's Range | 209.70 - 210.40 |
| 52-Week Range | 173.50 - 423.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amylo... [Read more]
News
Alnylam Pharmaceuticals Transcript: Investor update
The update highlighted zilebesiran's potential to transform hypertension care through continuous blood pressure control with twice-yearly dosing, supported by robust phase II data and a large ongoing phase III outcomes trial. Strategic investments and strong stakeholder enthusiasm position the therapy for broad impact if successful.
Alnylam Pharmaceuticals Slides: Investor update
Alnylam Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on September 17, 2026.
Alnylam Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
AMVUTTRA’s strong launch and robust clinical data have driven rapid growth, with a focus on expanding first-line use and broadening access. The pipeline features promising programs in Huntington’s disease, bleeding disorders, obesity, and hypertension, while international expansion and AI-driven innovation support long-term growth.
Alnylam Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference
AMVUTTRA's cardiomyopathy launch has driven strong revenue and first-line market growth, supported by robust access and favorable clinical data. Competitive risks have lessened with tafamidis exclusivity extended and a failed rival trial, while international expansion and pipeline progress in mivelsiran, Huntington's, and bleeding disorders continue to advance.
Alnylam price target raised to $260 from $230 at Jefferies
Jefferies raised the firm’s price target on Alnylam (ALNY) to $260 from $230 and keeps a Hold rating on the shares. After a recent recovery, the firm expects shares to…
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following ...
Alnylam announces new data at ESC Congress on AMVUTTRA
Alnylam (ALNY) Pharmaceuticals announced new data at the European Society of Cardiology, ESC, Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The finding...
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 20...
Alnylam Pharmaceuticals Slides: ESC Congress Presentation
Alnylam Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 30, 2026.
Alnylam to present new clinical data on ATTR, hypertension at ESC Congress
Alnylam (ALNY) Pharmaceuticals announced that it will present new clinical and real-world data across its transthyretin-mediated amyloidosis, ATTR, and hypertension programs at the European Society of...
Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data across its...
BMO Capital starts Alnylam at Outperform, sees attractive valuation
BMO Capital initiated coverage of Alnylam (ALNY) with an Outperform rating and $318 price target The company’s disappointing guidance during Q2 earnings piled on, bringing shares to current levels, bu...
Alnylam initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of Alnylam (ALNY) with an Outperform rating and $318 price target BMO rolled out coverage on nine biotechnology companies, saying each might be considered a “franchise”…
Alnylam award from Veterans Affairs posted to SAM.gov site
A contract award dated August 11 from Department of Veterans Affairs to Alnylam (ALNY) Pharmaceuticals was posted to the SAM.gov website. The total contract value for the base and all…
Alnylam price target lowered to $256 from $316 at Wells Fargo
Wells Fargo analyst Derek Archila lowered the firm’s price target on Alnylam (ALNY) to $256 from $316 and keeps an Equal Weight rating on the shares. The firm sees unfavorable…
Alnylam price target lowered to $325 from $400 at Evercore ISI
Evercore ISI lowered the firm’s price target on Alnylam (ALNY) to $325 from $400 and keeps an Outperform rating on the shares.
ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law
LOS ANGELES, Aug. 4, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnyl...
Alnylam price target lowered to $455 from $485 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Alnylam (ALNY) to $455 from $485 and keeps a Buy rating on the shares. Following the $200M midpoint reduction in full-year 2026…
Alnylam price target lowered to $315 from $410 at Truist
Truist lowered the firm’s price target on Alnylam (ALNY) to $315 from $410 and keeps a Buy rating on the shares. The outlook was tempered after weaker Amvuttra sales and…
Alnylam upgraded to Strong Buy from Outperform at Raymond James
Raymond James upgraded Alnylam (ALNY) to Strong Buy from Outperform with an unchanged price target of $420. The firm cites valuation for the upgrade with the shares down 35% since…
Alnylam price target lowered to $340 from $380 at Citi
Citi lowered the firm’s price target on Alnylam (ALNY) to $340 from $380 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q2…
Alnylam price target lowered to $450 from $527 at Barclays
Barclays analyst Eliana Merle lowered the firm’s price target on Alnylam (ALNY) to $450 from $527 and keeps an Overweight rating on the shares. The company reported a “disappointing” quarter…
Alnylam Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 net product revenues surged 74% year-over-year to $1.2 billion, led by AMVUTTRA’s strong first-line growth and robust U.S. and international demand. 2026 revenue guidance was revised down by $200 million due to normalized second-line demand, but long-term growth targets remain intact, supported by favorable market dynamics and pipeline progress.
Alnylam Pharmaceuticals Earnings release: Q2 2026
Alnylam Pharmaceuticals released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Alnylam Pharmaceuticals Quarterly report: Q2 2026
Alnylam Pharmaceuticals has published its Q2 2026 quarterly earnings report on July 30, 2026.